Hello and thank you for visiting our post on the CSL Share Price Forecast 2025, 2030, 2035, 2040, and 2050.
In the following article, we’ll examine the CSL Limited stock in great detail. Due to the numerous requests for stock research, we painstakingly worked to gather enough data on the company.
Therefore, before making any assumptions regarding the share price of CSL Limited, we will investigate the company’s activities and fundamentals.
So, pay attention all the way through this post, and let’s get started immediately.
About CSL Limited
As Commonwealth Serum Laboratories, a department of the Australian government devoted to the production of vaccines, CSL was established in 1916.
Under the direction of the organization’s founding director, William Penfold, CSL began operations in 1918 at the Royal Melbourne Hospital’s unoccupied Walter and Eliza Hall Institute building before relocating to its purpose-built Parkville facilities the following year.
In order to cure and prevent significant human medical problems, CSL Limited, an Australian multinational specialty biotechnology firm, conducts research, develops, produces, and promotes products.
Among the product categories supplied by CSL are cell culture reagents, vaccines, antivenom, and derivatives of blood plasma.
These products are used in several genetic and medical research projects as well as manufacturing processes.
Commonwealth Serum Laboratories was founded in 1916, and up to its privatization in 1994, the Australian federal government controlled 100 percent of the business.
Table of CSL Share Price Forecast 2023-2050
Target Year | 1st Target | 2nd Target |
2024 | $ 315.00 | $ 350.00 |
2025 | $ 345.00 | $ 410.00 |
2026 | $ 400.00 | $ 500.00 |
2027 | $ 480.00 | $ 620.00 |
2028 | $ 610.00 | $ 750.00 |
2029 | $ 730.00 | $ 890.00 |
2030 | $ 870.00 | $ 1,100.00 |
2035 | $ 2,510.00 | $ 2,950.00 |
2040 | $ 5,050.00 | $ 5,930.00 |
2050 | $ 10,800.00 | $ 12,000.00 |
Also Read: BHP Share Price Forecast 2025, 2030, 2035, 2040, 2050
CSL Share Price Forecast 2024
Revenue increase over FY23 is expected to be between 9 and 11% for FY24 when measured in constant currency.
For FY24, CSL expects its underlying profit, or NPATA, to be in the range of $2.9 billion to $3 billion at constant currency, which would represent an increase over FY23 of around 13-17%.
CSL Share Price Forecast 2024 is as follows –
Target Year | 1st Target | 2nd Target |
2024 | $ 315.00 | $ 350.00 |
Also Read: CBA Share Price Prediction 2025, 2030, 2035, 2040, 2050
CSL Share Price Forecast 2025
CSL reported a 31% growth in constant currency revenue to US$13.31 billion for the twelve months ending on June 30.
Growth across the board and an 11-month contribution from the new CSL Vifor business were the driving forces behind this.
CSL Share Price Forecast 2025 is as follows –
Target Year | 1st Target | 2nd Target |
2025 | $ 345.00 | $ 410.00 |
Also Read: Tesla Stock Price Prediction 2025, 2026, 2030, 2040, 2050
CSL Share Price Forecast 2026
The Total Equity Value, in this example US$123b, is obtained by adding the projected cash flows for the next 10 years to the discounted terminal value.
By dividing this amount by the total number of outstanding shares, we can get the intrinsic value per share.
The firm looks to be undervalued at a 32% discount to where the stock price now trades when compared to the current share price of AU$266.
CSL Share Price Forecast 2026 is as follows –
Target Year | 1st Target | 2nd Target |
2026 | $ 400.00 | $ 500.00 |
Also Read: Rivian Stock Price Prediction 2024, 2025, 2030, 2040, and 2050
CSL Share Price Forecast 2030
The Terminal Value, which takes into account all future cash flows after the first stage, must be determined once the Present Value of future cash flows in the initial 10-year period has been determined.
The Gordon Growth method is used to determine Terminal Value at a future yearly growth rate equal to the 2.0% yield on 10-year government bonds, which is the average for the previous five years.
CSL Share Price Forecast 2030 is as follows –
Target Year | 1st Target | 2nd Target |
2030 | $ 870.00 | $ 1,100.00 |
Conclusion
The CSL Share Price Forecast 2025 provides a glimpse into potential future trends for CSL Limited’s stock.
These forecasts offer investors valuable insights, but it’s essential to approach them with caution, as numerous unpredictable factors can impact stock performance.
While CSL’s historical growth and diversified product portfolio are positive indicators, prudent investors should exercise due diligence and consider broader market dynamics and economic conditions.
Relying solely on these forecasts may not be advisable. Seeking professional financial advice and staying informed about the company’s operations and market trends remain crucial for making well-informed investment decisions regarding CSL Limited.
Also Read: Michael Burry Net Worth 2023: Assets, Career and Awards
F.A.Q.
What does CSL Limited do?
CSL is a preeminent worldwide biotechnology business with a diverse range of life-saving drugs, including those that treat immunological deficiencies and hemophilia, as well as influenza vaccinations.
What does CSL Ltd stand for?
CSL stands for Commonwealth Serum Laboratories.
Is CSL Limited a good buy?
The FY26 PE for CSL should be 27x, which is in line with the 10-year trend. Continue to Buy.
The publication of the argenx trial results, which is anticipated for July, will act as the next trigger. With an outperform rating and a $326 price target, Macquarie is rated.